News & Events
What's new at PharmaMatrix
Publication releases, conferences, and clinical milestones for CCI-001.
- Publication
CCI-001 publication release
Our full peer-reviewed paper on CCI-001 efficacy in bladder and breast cancer models is released and available on the publications page in its entirety.
- Clinical
Phase 1 enrollment update - PMH-001
Continued patient enrollment in the PMH-001 Phase 1 study in bladder cancer (NCT04823897). Dose-escalation cohorts are progressing on schedule.
- Research
Expansion into breast cancer models
Preclinical data demonstrate strong activity of CCI-001 in triple-negative and HER2+ breast cancer cell lines, supporting the next stage of indication expansion.
- Company
International collaboration expanded
PharmaMatrix welcomed new academic collaborators in Europe and South America to support translational and computational workstreams.
- IP
European patent granted
The EPO granted PharmaMatrix's patent on novel colchicine derivatives, completing the trio of granted patents alongside the USPTO and CIPO.
- IP
Canadian patent granted
The Canadian Intellectual Property Office allowed PharmaMatrix's patent covering CCI-001 and related compounds.
- IP
US patent granted
The USPTO allowed PharmaMatrix's foundational composition-of-matter patent covering novel colchicine derivatives.
Media & press
Journalists and event organizers - get in touch for interviews or speaking requests.